ArticleMedicine2026
Absence of causal association between CD40-CD40L signaling and cervical cancer risk: A Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the potential causal relationship between cluster of differentiation 40 (CD40)-cluster of differentiation 40 ligand (CD40L) signaling and cervical cancer risk using a two-sample Mendelian randomization (MR) approach and to explore the expression and immune correlation of CD40/CD40L in cervical cancer. A two-sample MR framework was used in this study. Genetic instruments for CD40-CD40L (exposure) were derived from the plasma protein quantitative trait loci data. Summary-level data for cervical cancer (outcome) were obtained from 5 independent genome-wide association study datasets. Instrumental variable selection adhered to the core MR assumptions. Causal estimates were primarily generated using the inverse-variance weighted method supplemented by MR-Egger, weighted median, and other sensitivity analyses. Heterogeneity and pleiotropy were assessed. Bioinformatics analyses using the Sangerbox 3.0 and Gene Expression Profiling Interactive Analysis 2 databases were used to evaluate the expression, prognostic value, and immune infiltration correlation of CD40 and CD40L in cervical squamous cell carcinoma and endocervical adenocarcinoma. MR analyses found no significant causal effect of CD40-CD40L signaling on cervical cancer risk across all datasets (e.g., for CD40: inverse-variance weighted OR = 1.014, P = .838). Sensitivity analyses, including leave-one-out validation and tests for heterogeneity and horizontal pleiotropy, supported the robustness of null findings. Expression analysis showed no significant difference in CD40/CD40L mRNA levels between tumor and normal tissues and no correlation with overall survival. However, their expression was positively correlated with stromal, immune, and ESTIMATE scores in the tumor microenvironment. This MR study found no genetic evidence to support a causal role for CD40-CD40L signaling in cervical cancer etiology. Although not a causal risk factor, the positive correlation of CD40/CD40L expression with immune microenvironment scores suggests a potential role in local immune regulation, warranting further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.